LDN-0096738 | 103652-04-6

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: LDN-0096738
• 英文别名: iriginol hexaacetate；BM04B05；5,6,7-triacetoxy-3-(3,4,5-triacetoxy-phenyl)-chromen-4-one；5,6,7-Triacetoxy-3-(3,4,5-triacetoxy-phenyl)-chromen-4-on；Iriginol hexaaceatate；[2,3-diacetyloxy-5-(5,6,7-triacetyloxy-4-oxochromen-3-yl)phenyl] acetate
• CAS: 103652-04-6
• 化学式: C₂₇H₂₂O₁₄
• 分子量: 570.463
• InChiKey: VFQVOTVAPPYKEC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  41
• 可旋转键数：
  13
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  184
• 氢给体数：
  0
• 氢受体数：
  14

反应信息

• 作为产物：
  描述：

  LDN-0096812 、 乙酸酐 在 吡啶 作用下， 生成 LDN-0096738
  参考文献：
  名称：

  HALEY; BASSIN, Journal of the American Pharmaceutical Association (1961), 1951, vol. 40, # 2, p. 111 - 112

  摘要：

  DOI：

文献信息

• Plasminogen Activator Inhibitor-1 Inhibitors and Methods of Use Thereof to Modulate Lipid Metabolism
  申请人：Lawrence Daniel A.

  公开号：US20100137194A1

  公开（公告）日：2010-06-03

  The invention relates to plasminogen activator-1 (PAI-1) inhibitor compounds and uses thereof in the treatment of any disease or condition associated with elevated PAI-1. The invention includes, but is not limited to, the use of such compounds to modulate lipid metabolism and treat conditions associated with elevated PAI-1, cholesterol, or lipid levels.

  本发明涉及纤溶酶原激活剂-1（PAI-1）抑制剂化合物及其在治疗任何与升高的PAI-1相关的疾病或病状中的应用。本发明包括但不限于使用这些化合物来调节脂质代谢并治疗与升高的PAI-1、胆固醇或脂质水平相关的病症。
• PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITORS AND METHODS OF USE THEREOF TO MODULATE LIPID METABOLISM
  申请人：THE REGENTS OF THE UNIVERSITY OF MICHIGAN

  公开号：US20160009748A1

  公开（公告）日：2016-01-14

  The invention relates to plasminogen activator-1 (PAI-1) inhibitor compounds and uses thereof in the treatment of any disease or condition associated with elevated PAI-1. The invention includes, but is not limited to, the use of such compounds to modulate lipid metabolism and treat conditions associated with elevated PAI-1, cholesterol, or lipid levels.

  本发明涉及纤溶酶原激活物-1（PAI-1）抑制剂化合物及其在治疗与升高的PAI-1相关的任何疾病或病况中的用途。本发明包括但不限于使用这样的化合物来调节脂质代谢并治疗与升高的PAI-1、胆固醇或脂质水平相关的病症。
• Baker, Journal of the Chemical Society, 1928, p. 1029
  作者：Baker

  DOI：——

  日期：——
• Castration-Resistant Prostate Cancer
  申请人：NUtech Ventures

  公开号：US20160310528A1

  公开（公告）日：2016-10-27

  This invention relates to inhibitors of UDP-glucose dehydrogenase, and more particularly to UDP-glucose dehydrogenase inhibitors that are useful in the treatment of prostate cancer. Methods of inhibiting UDP-glucose dehydrogenase and improving the efficacy of additional prostate cancer therapies are also provided.
• US9120744B2
  申请人：——

  公开号：US9120744B2

  公开（公告）日：2015-09-01